References

1.	Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49(3):329–337. [CrossRef] [PubMed]
2.	Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109(15):1826–1833. [CrossRef] [PubMed]
3.	De Villiers CP, Van Der Merwe L, Crotti L, et al. AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. Circ Cardiovasc Genet. 2014;7(5):599–606. [CrossRef] [PubMed]
4.	Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci. 2007;104(52):20990-20995. [CrossRef] [PubMed]
5.	Niemeijer MN, van den Berg ME, Eijgelsheim M, Rijnbeek PR, Stricker BH. Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf. 2015;38(10):855-867. [CrossRef] [PubMed]
6.	Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol. 2013;37(1):9–19. [CrossRef] [PubMed]
7.	Newton-Cheh C, Larson MG, Corey DC, et al. QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: the Framingham Heart Study. Heart Rhythm. 2005;2(3):277–284. [CrossRef] [PubMed]
8.	Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George Jr AL, Murray KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm. 2005;2(2):134-140. [CrossRef] [PubMed]
9.	Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009;41(4):407–414. [CrossRef] [PubMed]